Company Overview and News
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
DOV.WI DOV RPM
Dover Corporation (DOV - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $72.45 to $74.91 in the past one month time frame.
CFIN RF.PRB RF.PRA DOV.WI KDP CIWV DOV RF GTLS
Dover Corporation (DOV - Free Report) reported second-quarter 2018 adjusted earnings per share from continuing operations of $1.30. The figure improved 21% from $1.07 recorded in the prior-year quarter, mainly driven by a strong overall demand environment. Earnings also beat the Zacks Consensus Estimate of $1.21. On a reported basis, Dover posted earnings per share of $1.08 in the quarter, which increased around 20% year over year.
WFC WFCNP ROP WFC.WS DOV.WI UNP WFC.PRL FCELB WFC.PRJ FCEL WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN DOV WBT WFC.PRY WFC.PRX WFC.PRW WFC.PRV GTLS
Dover Corporation (DOV - Free Report) is an industrial conglomerate producing wide range of specialized industrial products and manufacturing equipment. The company reported adjusted earnings of $1.30 per share in second-quarter 2018, beating the Zacks Consensus Estimate of $1.21. Earnings also improved 21% year over year mainly driven by strong overall demand environment. Revenue: Dover posted revenues of $1.
DOV.WI NBRV DOV EIGR NCS
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM C.WSA DOV.WI NOV TEL CVS FNF BAC C.WS.B CHTR APY.WI GM.WS.A FNFV C.WS.A GM.WS.B GM.WS.C C.PRP DOV C.PRU GM ORCL C.PRS LBRDB BAC C C.PRL AAL C.PRJ C.PRK BHGE COMM MA ARNC C.PRG TWC LBRDK C.PRC BHI C.PRPCL CGBBW OCLCF JLL LBRDA FL APY GM.WSB UNH
On Jun 30, Dover Corporation (DOV - Free Report) was downgraded to a Zacks Rank #5 (Strong Sell). The downgrade can be attributed to concerns regarding retail refrigeration business and cost woes. Going by the Zacks model, companies holding a Zacks Rank #5 have strong chances of underperforming the broader market. Also, Dover’s share price movement has not been much impressive. Over the past year, the company has underperformed the industry it belongs to.
WFC WFCNP ROP WFC.WS DOV.WI IEX WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN DOV WFC.PRY WFC.PRX WFC.PRW WFC.PRV GTLS
The Edge held the very first Spinoff conference in NYC on Wednesday, June 6 at the exclusive Penn Club on 44th St. to a packed room. With almost 100 nyc hedge fund managers, The Edge debated where, if any, Spinoffs make money. The event was non-profit, and all donations went to the Alzheimer’s Association. We are proud that, together, we raised $5,500. I was nervous, of course. How many times do I stand up in front of some of the smartest brains in the world? It was a great experience, and the thing I liked personally was that everyone was a winner.
CSC GD OLN DOV.WI DOV AXTA DXC.WI CC DXC
Dozens of major American companies are preparing to pull out of Iran as the Trump administration closes a narrow legal window that has allowed firms to operate there without violating U.S. sanctions.
HON GEC GE DOV.WI HON DOV GNE CB
Royal Dutch Shell (RDS.A) has expanded its robust upstream portfolio with the Dover discovery in the Gulf of Mexico. The company also kick-started production in the Kaikias field.
RDS.B DOV.WI RDS.A RYDBF DOV RDSB RDSA RYDAF
Dover Corporation (DOV - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for DOV broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
ELY DOV.WI DOV
It was a week where oil prices slumped below $70-a-barrel. However, natural gas futures edged closer to the psychologically important $3 level.
APA CQP RDS.B RDS.A DOV.WI LNG RDSB EPD RDSA VLO BHI REXX RXNRP REXXQ RYDBF DOV RYDAF RIG SGAZF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET